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talisations and 2.3 physician visits speciﬁcally for the treatment
of asthma exacerbations in the last 12 months. Patients in other
groups consumed more resources. Patients with mild persistent
asthma had 0.57 emergency room visits, 0.09 hospitalisations
and 3.1 physician visits. The means for moderate patients were
0.61, 0.25 and 3.66 respectively, and for severe patients 1.22,
1.98 and 6.22. Patients in Germany and France were most likely
to seek primary care treatment; though patients in Italy and the
UK were most likely to be hospitalised. CONCLUSION: The
data show that the likelihood of resource use of patients with
exacerbations of asthma increases with the underlying level of
severity. From these data, it is clear that better control and man-
agement of asthma exacerbations can result in resource use
savings.
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OBJECTIVES: To compare efﬁcacy and safety of salmeterol and
montelucast in adults with chronic bronchial asthma and cost-
effectiveness from payer’s and social perspective. METHODS:
The analysis was based on a systematic review. The efﬁcacy and
safety of salmeterol and montelucast were compared. Costs were
estimated on the basis of current cost of medication and pro-
ductivity loss in Poland. The time horizon of 12 weeks was
taken. The ratio of cost difference and efﬁcacy difference
(episode-free days—EFD) was calculated in incremental analy-
sis. RESULTS: The efﬁcacy analysis showed that statistically sig-
niﬁcant higher EFD ratio is achieved with salmeterol (32%) than
with montelucast (26%). Direct and indirect cost analyses of the
two options show that lower costs are generated by the use of
salmeterol. The use of montelucast in place of salmeterol results
in smaller health beneﬁt, and concomitantly, higher treatment
costs. The use of salmeterol in place of montelucast in a period
of 12 weeks in one patient is associated with gain of additional
5 days free of asthma symptoms. The estimated difference in a
period of 12 weeks of administration is approximately PLN 157
(34€) and PLN 248 (54€) per patient from payer’s and social per-
spective, respectively favouring salmeterol. The multivariate sen-
sitivity analysis was performed and conﬁrmed the robustness of
results. CONCLUSIONS: Salmeterol is a dominant option in
relation to montelucast in the treatment of bronchial asthma.
Salmeterol should be used before administration of montelucast.
Both perspectives concluded that administration of salmeterol
will result in payers budget savings—PLN680 (149€) per one
patient year. Conducting of prospective studies of indirect cost
of asthma treatment is recommended.
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OBJECTIVES: Assessment of efﬁcacy and safety of ﬂuticasone
and montelucast in treatment of adult patients with chronic
bronchial asthma and cost-effectiveness from payer’s and social
perspective. METHODS: Comparison of efﬁcacy and safety
were based on valid RCTs found in systematic reviews. Costs
were estimated on the basis of current cost of medications and
productivity loss in Poland. In the incremental analysis, the ratio
of social cost difference and efﬁcacy difference was calculated.
Multivariate sensitivity analysis was performed. RESULTS: Sta-
tistically signiﬁcantly higher efﬁcacy of ﬂuticasone over mon-
telucast has been demonstrated in relation to the following end
points: asthma symptom score, episode-free days, and supple-
mental rescue medications. There is no signiﬁcant difference
among treatment groups with respect to exacerbations and other
adverse events. Both options are safe and no difference in safety
has been demonstrated. The use of montelucast instead of ﬂuti-
casone results in smaller health beneﬁt for the patients, and con-
comitantly, higher treatment costs. The estimated difference in a
period of 24 weeks of administration is approximately PLN 733
(163€) and PLN 1401 (306€) per patient from payer’s and social
perspective, respectively favouring ﬂuticasone. The use of ﬂuti-
casone in place of montelucast for a period of 24 weeks in one
patient is associated with gained additional 14.6 days free of
asthma symptomps. Multivariate sensitivity analysis conﬁrmed
robustness of the results. CONCLUSIONS: Based on the con-
ducted cost-effectiveness analysis, it may be concluded that ﬂu-
ticasone is a dominant option over montelucast in the treatment
of bronchial asthma. Both perspectives concluded that adminis-
tration of ﬂuticasone will result in payers budget savings—
PLN1596 (348€) per one patient year. Prospective studies on
indirect costs of asthma treatment methods should be conducted.
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OBJECTIVES: Assess whether a disease management program
of asthma (DMPA) improves quality of care and reduces costs
compared to standard care (SC). METHODS: A prospective
“Before/After” quasi-experimental design was chosen. SC was
observed during the ﬁrst 18 months. DMPA involved training
doctors in existing guidelines in asthma, implementing asthma
education sessions and investments in computerised GP’s data
collection (with asthma template) Impact of DMPA was studied
in the subsequent 18 months. Control rate of asthma (CRA) was
deﬁned according to the Canadian asthma consensus criteria,
quality of life (QOL) measured by the Juniper scale and direct
and productivity costs assessed from the perspective of society.
The expenditure discount rate was three percent (3%). Three
regions were followed in parallel, to conﬁrm trends observed on
the experimental site were due to the DMPA. RESULTS: A total
of 32 volunteer general practitioners and 313 asthmatic patients
were recruited on the experimental site, of which 145 patients
took part in both phases of the study. There was an absolute
improvement on the average quarterly CRA of 11% (p < 0.003):
65% (±3%) in the DMPA group vs. 54% (±3%) for the SC
group; a relative gain of 20%. Differences in the patient’s QOL
were signiﬁcant in favour of DMPA (p < 0.05) for three domains
and on the overall score. Absolute reduction in the average quar-
terly costs reached 24% (p < 0.003): 247€ in the DMPA group
compared to 187.4€ for the SC group. Asthma drug costs were
not signiﬁcantly modiﬁed (p = 0.129). Meanwhile, in the paral-
